d7472c45-93c1-4237-82ac-c17e863b9a58
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.280
- ALLOGRAFT_REJECTION+0.210
- PROTEIN_SECRETION+0.170
- BILE_ACID_METABOLISM+0.120
- IL6_JAK_STAT3_SIGNALING+0.120
- HEME_METABOLISM+0.110
- INFLAMMATORY_RESPONSE+0.110
- PEROXISOME+0.100
- DNA_REPAIR+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ANGIOGENESIS-0.390
- APICAL_JUNCTION-0.390
- MITOTIC_SPINDLE-0.380
- MYOGENESIS-0.370
- APICAL_SURFACE-0.310
- HEDGEHOG_SIGNALING-0.300
- NOTCH_SIGNALING-0.260
- UV_RESPONSE_DN-0.260
- WNT_BETA_CATENIN_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1J6-01A-11R-A13Q-07 | — | B | 0.912 |
| 2 | MNG85 | — | — | 0.819 |
| 3 | SRR25617901 | — | B | 0.811 |
| 4 | SRR25617825 | — | C | 0.806 |
| 5 | SRR33532827 | — | D | 0.791 |
| 6 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.778 |
| 7 | TCGA-62-A472-01A-11R-A24H-07 | — | cohortA1 | 0.765 |
| 8 | SRR8518222 | — | D | 0.764 |
| 9 | SRR8518291 | — | D | 0.763 |
| 10 | s0122212 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.070 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |